Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Annual Report 2003 Aventis - Sanofi
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
Nutrition and <strong>Aventis</strong> CropScience in 2002. In addition,<br />
sales were negatively impacted by currency<br />
translation, which reduced reported net sales by<br />
approximately 9.4 %, principally due to the decline<br />
of the U.S. dollar and of Latin American currencies<br />
relative to the euro.<br />
The ongoing strong performance of strategic<br />
brands and vaccines were the primary drivers of the<br />
core business sales performance in <strong>2003</strong>. Sales of<br />
strategic brands (brand-name pharmaceuticals that<br />
we believe have signifi cant commercial potential<br />
and on which we focus our marketing efforts) and<br />
human vaccines totaled e 10 851 million, a 17.0 %<br />
>> 49